The Biotechnology Industry Organization announced a name change to the Biotechnology Innovation Organization, effective in early 2016.
The Biotechnology Industry Organization (BIO) will become the Biotechnology Innovation Organization in early 2016, announced Ron Cohen, CEO of Acorda Therapeutics, and the organization’s new board chair, during a June 17 keynote session at the 2015 BIO International Convention in Philadelphia.
“I’m pleased to announce that the BIO Board has approved a change to BIO’s name … from the Biotechnology Industry Organization to the Biotechnology Innovation Organization. Still BIO, but now with a name that better expresses the essence of what our member companies represent,” said Cohen.
“This is a great move that will help clarify for policymakers and the public the heart of our industry-scientific innovation that will help to heal, feed, and fuel the world. Each day, our members use cutting edge science and technology to deliver game-changing products, therapies, and cures to improve the human condition,” said BIO’s President and CEO, Jim Greenwood.
BIO is a trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.